Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
2021
Abstract Background The oral Janus kinase 1 (JAK1) inhibitor abrocitinib, which reduces interleukin-4 and interleukin-13 signaling, is being investigated for the treatment of atopic dermatitis. Dat...
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
13
References
26
Citations
NaN
KQI